

Jose Lutzky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6942624/publications.pdf>

Version: 2024-02-01

72
papers

19,740
citations

126708

33
h-index

110170

64
g-index

74
all docs

74
docs citations

74
times ranked

23503
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
2	Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. <i>Lancet Oncology</i> , The, 2010, 11, 155-164.	5.1	1,075
3	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
4	KIT as a Therapeutic Target in Metastatic Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2327.	3.8	755
5	Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. <i>British Journal of Haematology</i> , 2005, 129, 776-783.	1.2	378
6	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2397.	3.8	359
7	Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205. <i>Science Translational Medicine</i> , 2014, 6, 232ra51.	5.8	315
8	Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 955-962.	0.8	238
9	Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 492-493.	1.5	213
10	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 588-598.	12.5	177
11	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , the, 2019, 6, e459-e469.	2.2	174
12	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , the, 2019, 6, e448-e458.	2.2	168
13	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	0.8	145
14	Clinical and Immune Responses in Advanced Melanoma Patients Immunized With an Anti-Idiotypic Antibody Mimicking Disialoganglioside GD2. <i>Journal of Clinical Oncology</i> , 2000, 18, 376-376.	0.8	132
15	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. <i>Clinical Cancer Research</i> , 2015, 21, 2289-2296.	3.2	128
16	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3003-3003.	0.8	120
17	Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 7462-7469.	3.2	100
18	Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8032-8032.	0.8	97

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2647-2655.	0.8	94
20	Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. <i>British Journal of Haematology</i> , 2006, 135, 174-183.	1.2	74
21	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	0.5	69
22	Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 2402-2408.	3.2	66
23	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
24	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , 2018, 23, 193-202.	1.9	60
25	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
26	Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2009, 146, 619-626.	1.2	58
27	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. <i>Nature Communications</i> , 2020, 11, 6262.	5.8	50
28	A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. <i>Cancer</i> , 2019, 125, 1113-1123.	2.0	45
29	Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. , 2017, 5, 3.		44
30	Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3829-3838.	0.8	44
31	Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9030-9030.	0.8	44
32	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. <i>Cancer</i> , 2020, 126, 523-530.	2.0	43
33	Nodular Bleomycin Toxicity. <i>American Journal of Clinical Pathology</i> , 1989, 92, 101-104.	0.4	40
34	Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 6207-6212.	0.8	38
35	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256.	3.4	38
36	An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. <i>Melanoma Research</i> , 2005, 15, 283-285.	0.6	35

#	ARTICLE	IF	CITATIONS
37	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.. Journal of Clinical Oncology, 2020, 38, 10006-10006.	0.8	32
38	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. Clinical Genitourinary Cancer, 2017, 15, 31-41.e4.	0.9	31
39	Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIb-IVM1c melanoma. Melanoma Research, 2018, 28, 44-51.	0.6	31
40	Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease. Cancer Management and Research, 2015, 7, 47.	0.9	29
41	Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.. Blood, 2006, 108, 796-796.	0.6	25
42	Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.. Journal of Clinical Oncology, 2020, 38, 10004-10004.	0.8	19
43	Antibody-based vaccines for the treatment of melanoma. Seminars in Oncology, 2002, 29, 462-470.	0.8	16
44	A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.. Blood, 2004, 104, 333-333.	0.6	16
45	Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.. Journal of Clinical Oncology, 2017, 35, 3007-3007.	0.8	15
46	New Therapeutic Options in the Medical Management of Advanced Melanoma. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 249-257.	1.6	14
47	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
48	Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. Gynecologic Oncology, 1992, 45, 32-39.	0.6	10
49	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 439-445.	1.2	10
50	Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells. Cancer Chemotherapy and Pharmacology, 1991, 28, 93-101.	1.1	9
51	A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Investigational New Drugs, 2006, 24, 89-94.	1.2	8
52	A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.. Journal of Clinical Oncology, 2017, 35, 109-109.	0.8	8
53	Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIb/IV NSCLC.. Journal of Clinical Oncology, 2017, 35, 9085-9085.	0.8	7
54	Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. , 2021, 9, e003272.		6

#	ARTICLE	IF	CITATIONS
55	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. Journal of Clinical Oncology, 2019, 37, 9584-9584.	0.8	6
56	Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine after resection of high-risk melanoma.. Journal of Clinical Oncology, 2020, 38, 10017-10017.	0.8	6
57	Checkpoint inhibitors in the treatment of cutaneous malignant melanoma. Chinese Clinical Oncology, 2014, 3, 30.	0.4	6
58	Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.. Journal of Clinical Oncology, 2018, 36, 169-169.	0.8	5
59	A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS2648-TPS2648.	0.8	5
60	Velimogene aliplasimid. Expert Opinion on Biological Therapy, 2010, 10, 841-851.	1.4	4
61	Sequential administration of high-dose interleukin-2 and ipilimumab in patients with metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, e21041-e21041.	0.8	4
62	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. Journal of Clinical Oncology, 2018, 36, 4032-4032.	0.8	4
63	Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).. Journal of Clinical Oncology, 2019, 37, 9592-9592.	0.8	4
64	Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. , 2022, 10, e004839.		4
65	P865â€...Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies â€“ independent review committee data update. , 2020, , .		3
66	Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Supportive Care in Cancer, 2017, 25, 3217-3224.	1.0	2
67	Dynamics of tumor response in advanced melanoma patients treated with Cocksackievirus A21.. Journal of Clinical Oncology, 2016, 34, 9553-9553.	0.8	2
68	A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, TPS9595-TPS9595.	0.8	2
69	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144,) Tj ETQq1 1 0.784314 rgBT /Overlock systemic therapy.. Journal of Clinical Oncology, 2019, 37, 136-136.	0.8	2
70	Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNÎ² and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma.. Journal of Clinical Oncology, 2020, 38, TPS3161-TPS3161.	0.8	1
71	Collateral sensitivity to radiation and CIS-platinum in a multidrug-resistant human leukemia cell line. Cancer Chemotherapy and Pharmacology, 1995, 37, 168-172.	1.1	0
72	A randomized, controlled, open-label, phase 2 study of cemiplimab Â± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).. Journal of Clinical Oncology, 2022, 40, TPS9593-TPS9593.	0.8	0